Faster recovery after 25G than 20G vitrectomy

Article

But comparable functional and anatomical results in diabetic retinopathy patients

Twenty-five gauge (25G) microincision vitrectomy surgery (MIVS) can produce the same functional prognosis as conventional 20gauge (20G) vitrectomy in patients with proliferative diabetic retinopathy (PDR), but as the procedure is less traumatic for the eye, it reduces postoperative inflammation, induced astigmatism and patient discomfort, it is believed to result in faster recovery time compared with 20G vitrectomy. This means that MIVS has the potential to relieve the financial and temporal burdens of surgical treatment for PDR, representing great progress in the treatment of this complex vitreoretinal condition.

However, despite these advancements and despite the fact that 25G MIVS has now completely replaced 20G vitrectomy in some hospital settings, concrete data about the postoperative recovery period in the cases that underwent 25G MIVS had not previously been available. Therefore, Dr Tatsuhiko Sato (Osaka Rosai Hospital, Japan) and his team conducted a study1 to compare outcomes between the two procedures; specifically, they measured the duration of postoperative hospitalization (chosen as the index of postoperative recovery period) after 25G MIVS and compared it to that following 20G vitrectomy.

The team studied 159 eyes; the first group (n = 72) underwent 20G vitrectomy while the second group (n = 87) underwent 25G vitrectomy. There were no significant differences in patient demographics or preoperative ocular status between the two groups. All procedures were conducted by the same two experienced surgeons, working in a hospital that performs around 1000 vitreoretinal surgeries per year.

The researchers compared the surgical procedures and postoperative functional and anatomical outcomes between the two groups. Patients were permitted to be discharged from hospital when they displayed no signs of infection for five consecutive days after the vitrectomy, had no discomfort and no postoperative complications, such as retinal detachment and nonclearing vitreous haemorrhage. Eyes with vitreous cavities that were still filled with silicone oil at the last examination (baseline + ≥6 months) were classified as anatomical failures.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.